San Francisco, CA and Vancouver, BC – October 11th, 2017 – Innovative Targeting Solutions Inc. (ITS) today announced the successful achievement of its fourth milestone from its collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration utilizes Innovative Targeting Solutions’ proprietary HuTARG ™ research platform to discover antibody candidates useful for modulating immune responses in autoimmunity or cancer. The HuTARG ™ protein engineering platform is able to engineer both T-cell receptors and fully human antibodies that bind major histocompatibility complex (MHC)/peptide complexes displaying fragments of intracellular proteins of interest.
“The collaboration continues to highlight the strengths of the HuTARG™ platform”, said Paul Kang, CSO Innovative Targeting Solutions, “These are challenging targets and our continued success affirms the HuTARG™ technology’s disruptive potential as a pioneer in the antibody drug discovery and protein engineering field.”
Under the terms of the agreement, ITS is eligible for payments associated with the achievement of specified milestones. ITS is also eligible to receive royalty payments on sales of any products. Further details of the agreement are not being disclosed.
About Innovative Targeting Solutions Inc.
Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation protein engineering platform for the generation of fully human antibody and T cell receptor based therapeutics using its proprietary HuTARG ™ technology. The HuTARG ™ technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit www.innovativetargeting.com